Loading
intoDNA
A Krakow spin-out from the Jagiellonian University whose STRIDE assay counts individual DNA breaks in cells, sold to drug developers and aimed at predicting who responds to DNA-repair drugs.
Also called: intoDNA S.A.
Overview
intoDNA was founded in 2016 by researchers from the Jagiellonian University in Krakow to commercialise STRIDE, a fluorescence method that detects single- and double-strand DNA breaks directly in fixed cells. The company offers STRIDE as a contract research service to pharmaceutical and biotech companies developing DNA damage response drugs, radiosensitisers and chemotherapy combinations, and is working towards a functional companion test for PARP inhibitor response.
Connected
6Similar pages
- TechnologyHRD genomic scar scores (GIS, LOH, HRDetect)
Shares STRIDE DNA break detection (intoDNA), RAD51 foci assay (functional HRD test), HRD & BRCA testing, Ovarian cancer.
- IdeaA functional test for homologous recombination deficiency validated across laboratories
Shares HRD & BRCA testing, Ovarian cancer.
- Key paperHRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures
- TreatmentBRACAnalysis CDx
Shares HRD & BRCA testing, Ovarian cancer, Prostate cancer.
- PersonIsabelle Ray-Coquard
Shares HRD & BRCA testing, Ovarian cancer.
- PersonMary-Claire King
Shares HRD & BRCA testing, Ovarian cancer.
- CompanyMyriad Genetics
Shares HRD & BRCA testing, Ovarian cancer, Prostate cancer.
- TreatmentmyChoice CDx
Shares HRD & BRCA testing, Ovarian cancer.
Sources
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
intodna.com · 1
A source that has moved or gone is reported by the weekly link check. /audit/
ProvenanceLast edited 2026-09-17 · Jude Gomila · Header star count stays put on reload; counts grid fills… · diff · file
Sourced, not expert-reviewed